Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2025 Aug;13(8):102492.
doi: 10.1016/j.jchf.2025.03.038. Epub 2025 Jun 13.

Contemporary Epidemiology, Management, and In-Hospital Outcomes of Acute Myocarditis: The Prospective Multicenter MyocarditIRM Study

Collaborators, Affiliations
Observational Study

Contemporary Epidemiology, Management, and In-Hospital Outcomes of Acute Myocarditis: The Prospective Multicenter MyocarditIRM Study

Claire Bouleti et al. JACC Heart Fail. 2025 Aug.

Abstract

Background: Despite a frequently favorable evolution during the initial phase, acute myocarditis (AM) remains associated with heart failure and ventricular arrhythmia. There are no large prospective databases to provide robust results.

Objectives: The aim of this study was to describe baseline characteristics, real-life management, in-hospital outcomes, and determinants of prognosis in a large cohort of patients with AM admitted to cardiology, with a comparison of patients with and without initial severity criteria.

Methods: MyocarditIRM (French National Observatory Tracking Viral Myocarditis: Mortality, Cardiovascular Events, Sequels on [Magnetic Resonance Imaging] MRI) is a multicenter prospective observational study of patients with AM confirmed by cardiac magnetic resonance. Patients initially admitted to the intensive care unit or those who died before cardiac magnetic resonance-confirmed diagnosis were not included.

Results: In total, 803 consecutive hospitalized patients were enrolled at 49 participating centers between May 2016 and February 2019. The median age was 31 years (Q1-Q3: 23-41 years), and 82% were men. Chest pain was the most frequent symptom (93%), and 112 patients (14%) had severity criteria upon admission (left ventricular ejection fraction <50%, severe ventricular arrythmia, high-degree atrioventricular block, or cardiogenic shock). ST-segment elevation was observed in 49% of patients. Overall, 64 patients (8%) experienced in-hospital complications, defined as a composite of death; left ventricular ejection fraction ≤40%; sustained ventricular or supraventricular arrythmia; cardiogenic shock; and need for mechanical circulatory support, inotropic drugs, temporary cardiac pacing, pacemaker, or cardiac defibrillator implantation. Patients with severity criteria at admission were 10 times more likely to experience in-hospital complications.

Conclusions: This prospective cohort represents the largest AM database worldwide. Although the recruitment process likely led to a selection of patients with lower risk AM, 8% experienced in-hospital complications, the major prognosis factor being severity criteria upon admission. (French National Observatory Tracking Viral Myocarditis: Mortality, Cardiovascular Events, Sequels on (Magnetic Resonance Imaging) MRI; NCT02717143).

Keywords: CMR; acute myocarditis; management; prognosis.

PubMed Disclaimer

Conflict of interest statement

Funding Support and Author Disclosures MyocarditIRM is an academic study funded by the French Society of Cardiology (unrestricted grant), the French Society of Radiology, and the French Society of Cardiac and Vascular Imaging. Dr Bouleti has received consulting and lecture fees from AstraZeneca, Novartis, Boehringer Ingelheim, and Sanofi; has a research contract with Janssen; and has received grants from Pfizer. Dr Angoulvant has received fees for lectures, presentations, Speakers Bureau participation, and educational events from Amgen, Alnylam, Amarin, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Bouchara Recordati, Pfizer, Novartis, Novo Nordisk, Organon, Sanofi, Servier, and Vifor. Dr Ternacle is a consultant for Philips Healthcare and General Electric. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Publication types

Associated data